StockNews.AI
ARTL
StockNews.AI
141 days

Artelo Biosciences to Present Novel Scientific Insights for ART26.12 at the 4th ACE Drug Discovery Summit on April 3, 2025

1. Artelo's presentation on FABP5 at ACE Summit on April 3. 2. ART26.12 show promise in treating neuropathic pain and cancers. 3. Phase 1 trial data for ART26.12 expected in Q2 2025. 4. FABP5 inhibition linked to various therapeutic developments. 5. Artelo aims to address unmet needs in significant diseases.

8m saved
Insight
Article

FAQ

Why Bullish?

The upcoming presentation and promising trial data can elevate investor interest, mirroring past success with similar announcements in biotech sectors that led to stock price increases. For instance, other biotech firms often see stock appreciation following significant clinical trial updates or key presentations at industry conferences.

How important is it?

The article highlights a key upcoming event that may significantly affect ARTL's performance in the market. Given the advanced stage of clinical trials and the focus on innovative pain management solutions, the implications are relevant for stakeholders.

Why Short Term?

The anticipated Phase 1 trial data in Q2 2025, along with visibility from the ICO presentation, can lead to immediate investor reactions. Previous companies experience short-term stock movements following conference presentations and data releases.

Related Companies

NLSTEXASRGENVRTXBIIB
March 31, 2025 08:30 ET  | Source: Artelo Biosciences SOLANA BEACH, Calif., March 31, 2025 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today announced that Myles Osborn, Lead Medicinal Chemist at Artelo Biosciences, will be presenting at 12:30pm BST on April 3, 2025 during the 4th ACE Drug Discovery Summit being held at The Insurance Hall, London, UK. In the course of the presentation, titled “Comparative Multi-Omics to Interrogate Consensus Mechanisms of FABP5i Across Diverse Indications,” Mr. Osborn will discuss an analysis of multiple datasets across different disease models related to deeper understanding of the impact of downstream biology of Fatty Acid Binding Protein 5 (FABP5) inhibition and share new insights by which this novel target may impact therapeutic developments across a wide array of potential indications. FABP5 plays a key role within cellular communication pathways and inhibition of the target has demonstrated activity in models of neuropathic pain, osteoarthritis, cancer, and cancer bone pain. A Phase 1 Single Ascending Dose study in healthy volunteers with ART26.12, Artelo’s lead FABP5 inhibitor, is nearing completion with data expected in Q2 2025. About ART26.12ART26.12, Artelo’s lead Fatty Acid Binding Protein 5 (FABP5) inhibitor, is being developed as a novel, peripherally acting, non-opioid, non-steroidal analgesic. Cleared by the FDA for a first-in-human study in the US, data from the first Phase 1 trial with ART26.12 is anticipated in Q2 2025. The initial clinical development planned is for chemotherapy-induced peripheral neuropathy (CIPN). Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids important to normal cellular function. FABP is overexpressed and associated with abnormal lipid signaling in a number of pathologies. In addition to ART26.12 in CIPN, Artelo’s extensive library of small molecule inhibitors of FABPs has shown therapeutic promise for the treatment of certain cancers, neuropathic and nociceptive pain, psoriasis, and anxiety disorders. About Artelo BiosciencesArtelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, neuropathy, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio. About ACE Drug Discovery SummitThe 4th ACE Drug Discovery Summit, 2025 provides a platform for scientists, researchers, and decision makers from all over the world debate on the latest scientific advances, trends, current challenges and futuristic advancements in Drug Discovery. The two-day conference is designed to maximize collaborations and innovation discussions among pharma and technology experts with presentations and interactive sessions between professionals from industry and academia. The Summit features cutting edge scientific advancements in the areas of drug discovery, AI, screening automation, high content imaging, disease modelling, cell and gene therapy. To register for the ACE Drug Discovery Summit, please visit: https://acxpo.com/4th-ace-drug-discovery-summit/ Forward Looking StatementsThis press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws. Investor Relations Contact:Crescendo Communications, LLCTel: 212-671-1020Email: ARTL@crescendo-ir.com 

Related News